Vascular endothelial growth factors (VEGFs) are key mediator of retinal and choroidal neovascularization as well vascular leakage leading to macular edema. As such, VEGF plays an important role in mediating visually significant complications associated with common disorders such diabetic retinopathy, vein occlusion, age-related degeneration. Various drugs that inhibit (anti-VEGF therapies) have...

Randomized clinical trials showed that maintenance chemotherapy plus biologics in patients with mCRC could increase the progression free survival (PFS) without any advantage for overall (OS). Our aim was to study real-life experience (onco-colon registry Turkey) of antiEGFR or antiVEGF mAbs after standart firstline doublet backbone RAS wild-type patients. This multicenter, retrospective aimed e...

Background: Nanotechnology symbolizes a broad discipline with enormous potential in cancer treatment bridging one of the bottlenecks traditional approaches therapy which is an inability to deliver adequate quantities anti-cancer drugs tumor area. Studies on nanoparticles indicate their importance angiogenesis and metastasis. Aim: The present study assessed anti-angiogenesis anti-metastatic effe...


 CADTH recommends that Beovu be reimbursed by public drug plans for the treatment of diabetic macular edema (DME) if certain conditions are met.
 should covered to treat patients with DME provided is a similar patient population and in way other anti–vascular endothelial growth factor (VEGF) drugs currently adult DME.
 only prescribed an ophthalmologist experience managing its c...


 CADTH recommends that Vabysmo be reimbursed by public drug plans for the treatment of diabetic macular edema (DME) if certain conditions are met.
 should covered to treat patients with DME provided it is a similar patient population and in way other anti–vascular endothelial growth factor (VEGF) drugs currently adult DME.
 only prescribed an ophthalmologist experience managing ...

Systemic therapy with anti-VEGF drugs such as bevacizumab is widely used for treatment of human patients with various solid tumors. However, systemic impacts of such drugs in host healthy vasculatures remain poorly understood. Here, we show that, in mice, systemic delivery of an anti-VEGF or an anti-VEGF receptor (VEGFR)-2 neutralizing antibody caused global vascular regression. Among all exami...

Wet age-related macular degeneration (wet AMD) is the most common cause of blindness, and chronic intravitreal injection anti-vascular endothelial growth factor (VEGF) proteins has been dominant therapeutic approach. Less a prolonged inter-injection interval are main drivers behind new wet AMD drug innovations. By rationally engineering surface residues model anti-VEGF nanobody, we obtained ser...

Background: Over the past decade, treatment landscape for advanced hepatocellular carcinoma (HCC) has expanded considerably. Therefore, this network meta-analysis aimed to compare efficacy of combination versus sorafenib. Materials and Methods: A systematic literature review was conducted select eligible studies. performed overall survival (OS) objective respon...

Alterations in the biological activity of molecules under stress conditions have not been documented as widely literature yet. This study was designed to reveal functional impacts various oxidation on a model mAb, commercial anti-VEGF IgG molecule. The responses antigen binding, cell proliferation, FcRn receptors, and C1q which rarely appear current literature, were investigated. authors report...